Verona Pharma Investor Relations Material
Latest events
Q1 2025
Verona Pharma
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Verona Pharma plc
Access all reports
Verona Pharma plc is a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of respiratory diseases. Its main product, ensifentrine, is designed to alleviate symptoms and improve health outcomes in conditions such as chronic obstructive pulmonary disease (COPD). The company is headquartered in London, United Kingdom, and its shares are listed on the NASDAQ.
Key slides for Verona Pharma plc
Investor Presentation
Verona Pharma plc
Investor Presentation
Verona Pharma plc
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
VRNA
Country
🇺🇸 United States